CEOi and Why it Matters in the Alzheimer’s Fight

By 2050, an estimated 115 million people worldwide will have been diagnosed with Alzheimer’s, making clear the need to accelerate dementia research and development timelines. Last week’s Global Dementia Legacy Event in Ottawa really served to drive home the importance of working together as an international community to tackle dementia. Another vital international coalition that has been formed to guide the battle against this disease is the Global CEO Initiative on Alzheimer’s Disease (CEOi).

The CEOi represents a worldwide public-private partnership between global corporations and non-profit and government organizations to provide social, fiscal, and political leadership in the quest to stop Alzheimer’s. With 44 million people worldwide currently living with Alzheimer’s and dementia, this partnership aims to spur much-needed medical discoveries that will improve diagnosis, prevention, treatment, and care of those afflicted with this debilitating disease.

As a company that has been deep in the trenches of the battle against Alzheimer’s for the past 25 years, Lilly was happy to take on a formational role in the creation of this partnership. The coalition’s drive to stop Alzheimer’s by 2025 fits perfectly with our own mission and we’re deeply committed to advancing this initiative with all of our available resources. By working together, we can change the game on Alzheimer’s to accelerate the means to diagnose, prevent, and treat this disease that affects millions of people.